Page 785«..1020..784785786787..790800..»

UK feed and pig industries welcome UK consultation on gene editing – FeedNavigator.com

Posted: January 8, 2021 at 3:48 pm

Robert Sheasby, CEO of the AIC, the voice of the UK feed and the agri-supply sector, said:

The AIC warmly welcomes the launch of this government consultation on gene editing in crops and livestock. We have long sought to support sustainable modern commercial agriculture in the UK, and this is the opportunity for our members to put forward their views on this development in technology. We would encourage the industry at large to respond.

EU legislation controlling the use of GMOs was retained in the UK at the end of the transition period, after December 31, 2020. This retained legislation requires that all GE organisms are classified as GMOs irrespective of whether they could be produced by traditional breeding methods.

The UK's Department of Food, Rural Affairs and the Environment (Defra) said it is its view that organisms produced by GE or by other genetic technologies should not be regulated as GMOs if they could have been produced by traditional breeding methods.

Leaving the EU provides an opportunity to consult on the implications of addressing this issue. We recognize there is a spectrum of opinions on these topics, and we are consulting to provide an opportunity for all views to be shared."

Speaking at the Oxford Farming Conference, where the consultation was launched, UK environment secretary, George Eustice, said:

Gene editing has the ability to harness the genetic resources that mother nature has provided, in order to tackle the challenges of our age. This includes breeding crops that perform better, reducing costs to farmers and impacts on the environment, and helping us all adapt to the challenges of climate change.Its potential was blocked by a European Court of Justice ruling in 2018, which is flawed and stifling to scientific progress. Now that we have left the EU, we are free to make coherent policy decisions based on science and evidence. That begins with this consultation.

Consulting with academia, environmental groups, the food and farming sectors and the public is the beginning of this process that, depending on the outcome, will require primary legislation scrutinized and approved by the UK parliament, stressed Defra.

Professor Robin May, the chief scientific officer of the UKs Food Standards Agency (FSA), also welcomed the review, saying:

The UK prides itself in having the very highest standards of food safety, and there are strict controls on GM crops, seeds and food which the FSA will continue to apply moving forward. As with all novel foods, GE foods will only be permitted to be marketed if they are judged to not present a risk to health, not to mislead consumers, and not have lower nutritional value than existing equivalent foods. We will continue to put the consumer first and be transparent and open in our decision-making. Any possible change would be based on an appropriate risk assessment that looks at the best available science.

Sir David Baulcombe, professor of botany in the Department of Plant Sciences at the University of Cambridge, said the overwhelming view of public sector scientists is that the Nobel Prize winning methods for gene editing can accelerate the availability of crops and livestock for sustainable, productive and profitable agriculture.

The UK National Pig Association (NPA) said that gene editing technology could potentially deliver long-term benefits for pig production.

In the NPA's response to the Nuffield Council of Bioethics call for evidence on genome editing in September 2019, its senior policy adviser, Rebecca Veale, identified the potential value of gene editing tools in improving the efficiency of pig production.

"The opportunities for application are long. We might be in a better place to tackle diseases such as ASF and PRRS and we might be able to reduce emissions in pig production or exploit nutritional availability in feed better.

"Afew countries have made small steps to utilizing this technology, but these have been limited. Our industry cannot be disadvantaged by a lack of access to such a tool and any future policy must be clear not to breach ethical boundaries, but to have flexibility to allow the use of the technology to be exploited to its full potential. Any future developments are reliant on support for the research required to explore the opportunities available, she added.

Responding to the consultation, the director of anti-GM campaign group, GM Freeze, Liz ONeill said:

"People have many concerns about the use of genetic engineering in food and farming so public engagement is vital but it has to be done well. Unfortunately this consultation has started very badly. Its been launched in the midst of an unprecedented health crisis; it has a clear bias in favour of removing vital safeguards; and the text of the consultation grossly misrepresents the nature of highly experimental new GM techniques.

"Instead of working with people to understand their concerns, Defra is pushing the high-tech, quick-fix agenda favoured by industrial farming corporations. GM Freeze will, of course, be submitting evidence and we encourage everyone who wants to know what they are eating to do the same, but the government should be doing much more to protect our food, our farms and the natural environment."

Aside from gene editing, the consultation will also begin a longer-term project to gather evidence on updating the UK approach to genetic modification by gathering information on what controls are needed and how best to deliver them, said Defra.

Continued here:
UK feed and pig industries welcome UK consultation on gene editing - FeedNavigator.com

Posted in Genetic Engineering | Comments Off on UK feed and pig industries welcome UK consultation on gene editing – FeedNavigator.com

Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change – Market is Expected to Recover to Reach $1.55 Billion in 2023 – Forecast to…

Posted: January 8, 2021 at 3:48 pm

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global crispr technology market.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The CRISPR technology market consists of sales of CRISPR technology products and services which is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. The revenue generated by the market includes the sales of products such as design tools, plasmid & vector, Cas9 & gRNA, libraries & delivery system products and services that include design & vector construction, screening and cell line engineering.

These products and services are used in genome editing/genetic engineering, genetically modifying organisms, agricultural biotechnology and others which include gRNA database/gene library, CRISPR plasmid, human stem cell & cell line engineering by end-users. The end-users include pharmaceutical & biopharmaceutical companies, biotechnology companies, academic & research institutes and contract research organizations.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

In 2019, Cardea Bio Inc., a US-based biotechnology infrastructure company that manufactures biology-gated transistors (Cardean transistors) that utilizes biocompatible graphene instead of silicon and replaces optical signal observations with direct electrical molecular signal analysis, merged with Nanosens Innovations, Inc. The merger is aimed at accelerating the development of the genome sensor that combines Nanosens' CRISPR-Chip technology with Cardea's graphene biosensor infrastructure and is the first DNA search engine globally that runs on CRISPR-Chip technology. Nanosens will be operating as a subsidiary of Cardea Bio. Nanosens Innovations, Inc. is a US-based biotechnology company that develops CRISPR-Chip and FEB technology.

The CRISPR technology market covered in this report is segmented by product type into design tools; plasmid and vector; CAS9 and G-RNA; delivery system products. It is also segmented by application into genome editing/ genetic engineering; genetically modified organisms; agricultural biotechnology; others and by end-user into industrial biotech; biological research; agricultural research; therapeutics and drug discovery.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing. In July 2018, the Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation.

In April 2019, the Australian government stated that the Office of the Gene Technology Regulator (OGTR) will regulate only the gene-editing technologies that use a template, or that insert other genetic material into the cell. According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the market.

Several advancements in CRISPR technology are trending in the market during the period. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more. In 2019, a study published in Springer Nature stated the development of an advanced super-precise new CRISPR tool that allows researchers more control over DNA changes. This tool seems to have the capability of providing a wider variety of gene edits which might potentially open up conditions that have challenged gene-editors.

Also, in 2020, another study in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR-Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test.

This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

Key Topics Covered:

1. Executive Summary

2. CRISPR Technology Market Characteristics

3. CRISPR Technology Market Size And Growth

3.1. Global CRISPR Technology Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global CRISPR Technology Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. CRISPR Technology Market Segmentation

4.1. Global CRISPR Technology Market, Segmentation By Product Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global CRISPR Technology Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.3. Global CRISPR Technology Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. CRISPR Technology Market Regional And Country Analysis 5.1. Global CRISPR Technology Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global CRISPR Technology Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/vnvkue

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:
Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to...

Posted in Genetic Engineering | Comments Off on Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change – Market is Expected to Recover to Reach $1.55 Billion in 2023 – Forecast to…

5 questions facing gene therapy in 2021 – BioPharma Dive

Posted: January 8, 2021 at 3:48 pm

Three years ago, the Food and Drug Administration granted a landmark approval to the first gene therapy for an inherited disease, clearing a blindness treatment called Luxturna.

Since then, the regulator has approved one more gene therapy,the spinal muscular atrophy treatment Zolgensma, and given a green light for dozens of biotech and pharmaceutical companies to start clinical testing on others. Genetic medicines for a range of diseases, including hemophilia, sickle cell and several muscular dystrophies, appear in reach, and new science is galvanizing research.

But, entering 2021, the gene therapy field faces major questions after a series of regulatory and clinical setbacks have shaded optimism. "The ups and downs of adolescence are on full display" analysts at Piper Sandler wrote in September, summing up the state of gene therapy research.

Here are five questions facing scientists, drugmakers and investors this year. How they're answered will matter greatly to the patients and families holding out hope for one-time disease treatments.

The FDA was widely expected last year to approve a closely watched gene therapy for hemophilia A, the more common type of the blood disease. Instead, the agency in August surprisingly rejected the treatment, called Roctavian, and asked its developer, BioMarin Pharmaceutical, to gather more data.

The next day, Audentes Therapeutics reported news came a third clinical trial participant had died after receiving the biotech's experimental gene therapy for a rare neuromuscular disease. The tragedy brought flashbacks to past safety scares in gene therapy, although the current wave of treatments being tested have generally appeared safe.

A little less than five months later, the gene therapy field is grappling with two more setbacks. UniQure is exploring whether a study volunteer's liver cancer was caused by its gene therapy for hemophilia B. And Sarepta, one of the sector's top developers, faces significant doubts about its top treatment for Duchenne muscular dystrophy after disclosing a key study missed one of its main goals.

In each case, the drugmakers involved offered explanations and reasons for optimism. BioMarin still expects to obtain an approval; Audentes' trial is now cleared by the FDA to resume testing; UniQure thinks it's unlikely the cancer case is linked to treatment; and Sarepta argued its negative data were the product of unlucky study design.

But taken together, the developments are powerful reminders of both the stakes and uncertainty still facing gene therapy.

All four events also highlighted lingering worries about one-time genetic treatment. In rejecting Roctavian, for example, the FDA seemed to be concerned the impressive benefit hemophilia patients initially experienced may wane over time. The deaths in Audentes' study, meanwhile,renewed warnings about extremely high doses of gene therapy. Researchers have long watched for evidence that replacing or altering genes may cause cancer to develop in rare instances, particularly after four infants developed leukemia in a gene therapy study in the early 2000s.And Sarepta's negative findings were surprising because early signs of dramatic biological benefit that didn't seem to translate into clear-cut functional gains for all patients.

Experts are still confident gene therapy can deliver on its promise. Bu recent events suggest getting there may take a bit longer than some expected.

"The process is the product," is an often-used cliche about gene therapy, which are complex treatments with exacting manufacturing standards.

Most of the roughly 60,000 pages in Spark Therapeutics' application for approval of Luxturna, for instance, involved what's known in the industry as "chemistry, manufacturing and controls."

The therapeutic basis for gene therapy, by contrast, is much clearer for many of the rare, monogenic diseases that developers are targeting. If mutations in a single gene lead to disease, replacing or otherwise fixing that gene should have a large benefit.

"Genetic medicine is not industrialized serendipity," said Gbola Amusa, an analyst at Chardan, contrasting gene therapy with chemical-based drugs."It often is an engineering question."

In 2020, the FDA gave ample notice that it's watching gene (and cell) therapy manufacturing closely.Sarepta,Voyager Therapeutics,Iovance Biotherapeuticsand Bluebird biowere all forced to revise their development timelines after the agency asked for new details about production processes.

"The FDA is saying to companies that you've got to up your standards," Amusa added.

For their part, FDA officials have indicated the spate of data requests are a product of the sharply higher numbers of companies advancing through clinical testing.

While setbacks have piled up for therapies that seek to replace genes, 2020 was a "transformative year" for therapies designed to edit them, according to Geulah Livshits, an analyst at Chardan.

CRISPR gene editing, already widely recognized as a scientific breakthrough, gained further prestige with the awarding of the Nobel Prize in Chemistry to two early pioneers, Jennifer Doudna and Emmanuelle Charpentier.

But the year also brought important progress from early biotech adopters.Editas Medicine and Intellia Therapeutics, for example, notched CRISPR firsts with use of the editing technology inside the human body.

And CRISPR Therapeutics and partner Vertex showed their experimental therapy, which uses CRISPR to edit stem cells, worked exceptionally well in the first 10 patients with either sickle cell disease or beta thalassemia treated in two early studies.

The data are the most concrete sign yet that CRISPR's clinical use can live up to its laboratory promise. While all three companies' therapies are still in early stages, their advances have ginned up substantial investor enthusiasm.

Together, the market value of CRISPR Therapeutics, Editas and Intellia totals nearly $25 billion. Beam Therapeutics, a startup that uses a more precise form of gene editing, is worth nearly $6 billion.

"Gene therapy will have a big role to play," said John Evans, Beam's CEO. "But I do think in the last year or so there's a growing realization that, when possible, you'd probably rather edit than add an extra gene."

Clinical tests will prove that out but, until then, the large upswing in share price for gene editing companies may not be sustainable as valuations creep higher and higher. Some of the recent run-up, for instance,appears driven by money flowing from generalist investors through exchange-trade funds, rather than from investors experienced in handicapping preclinical- or early clinical-stage companies.

"They're overdue for some type of rationalization," predicted Brad Loncar, CEO of Loncar Investments, adding that many companies are targeting similar diseases, most commonly sickle cell and beta thalassemia.

Tasked with replacing faulty genes with functional ones, scientists for the most part have turned to two types of viruses to safely shuttle genetic instructions into cells. Adeno-associated viruses, or AAVs,are typically used for infused treatments, while researchers working on cells extracted from patients generally opt for lentiviruses.

Each virus class has advantages, but also notable drawbacks. AAVs, for instance, can trigger pre-existing immune defenses in some people, making those individuals ineligible or poor candidates for gene therapy. Lentiviruses, by contrast, are known to integrate their DNA directly into the genomes of cells they infect a useful attribute in some regards but limiting in others.

Over decades of gene therapy research, scientists have found ways to tweak and modify these viral vectors to better suit their needs, but the basic tools are the same. Jim Wilson, a gene therapy pioneer who ran the study that led to the death of teenager Jesse Gelsinger in 1999, told attendees at a STAT conference last fall that he's "somewhat disappointed" by slow progress in viral vector research.

And as more and more gene therapies enter clinical testing, the limitations of current viral vectors have become more apparent.

The pace of research might be picking up, however. Recently, a number of companies aiming to build better delivery tools have launched, including Harvard University spinout Dyno Therapeutics and 4D Molecular Therapeutics, which recently raised $222 million in an initial public offering.

Larger companies are interested, too. Roche, Sarepta and Novartis have all partnered with Dyno, for example.

In gene editing, meanwhile, researchers are developing new ways to cut DNA, while Beam and others are advancing different editing approaches altogether.

Billions of dollars have flowed from pharmaceutical companies into gene therapy over the past few years, leaving few large multinational drugmakers without a research presence.

2020 was no different, with sizable acquisitions inked by Bayer and Eli Lilly, as well as an array of smaller investments from Pfizer, Novartis, Johnson & Johnson, Biogen,and UCB. And CSL Behring, best known for its blood plasma products, spent nearly half a billion dollars to buy UniQure's most advanced gene therapy, a treatment for hemophilia B.

Over the past three years, there's been at least $30 billion spent on biotechs involved in gene or cell therapy. (Four deals account for the majority of that value.)

All of that dealmaking, while following promising and compelling science, is ultimately a bet that one-time genetic treatments can be scaled up and commercialized into a lucrative business.

Many of the acquired companies are working on therapies for very rare disorders affecting hundreds or thousands of people. A handful, however, are taking aim at more prevalent conditions, starting with still relatively uncommon diseases like hemophilia to ones affecting millions of people like Parkinson's.

"For gene therapy to meet our lofty expectations not just for investors, but for society it has to make the leap from these ultra-rare diseases," said Loncar.

Commercially, the track record for the few therapies on the market in the U.S. is mixed.Luxturna, now owned by Roche, is a niche product.Zolgensma has broader use and earned Novartis about $1 billion in the year and a half it's been commercially available.

Two cell therapies from Novartis and Gilead, meanwhile, have struggled to gain traction.

Gene therapy's biggest commercial test yet was supposed to come this year, with the expected approval of BioMarin's Roctavian in hemophilia A. The FDA's surprise rejection could mean a yearslong delay in the U.S., but the challenges of pricing, reimbursement and patient access in gene therapy remain dauntingly large.

Read the rest here:
5 questions facing gene therapy in 2021 - BioPharma Dive

Posted in Genetic Engineering | Comments Off on 5 questions facing gene therapy in 2021 – BioPharma Dive

Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |…

Posted: January 8, 2021 at 3:48 pm

DetailsCategory: DNA RNA and CellsPublished on Friday, 08 January 2021 07:36Hits: 232

-- Focuses on immuno-oncology

-- Creates innovative, engineered T and NK cells from induced pluripotent stem cells (iPSC)

-- In-licenses mRNA technologies developed by Factor Bioscience

-- Uses mRNA-based approach to create cell therapies - avoids viruses and DNA

-- Names key executives including Gregory Fiore, MD, as Chief Executive Officer

CAMBRIDGE, MA, USA I January 6, 2021 I Exacis Biotherapeutics, Inc., a development-stageimmuno-oncology company working to harness the immune system to cure cancer,today announcedits formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis'next generation approachavoids useof DNA andviruses by usingmRNA.The technologies will be used for generatingiPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-Tor ExaCAR-NKcells.

Exacis also announcedthe addition of key members to its leadership team, Scientific Advisory Board and Board of Directors. Gregory Fiore, MD,a Harvard trained physician, seasoned pharmaceutical executiveand serial entrepreneur, has been named Chief Executive Officer.Dr. Fiore is joined on the management team by co-founder and Head of Discovery and Development, James Pan, PhD,an entrepreneur andbiologics expert. DimitriosGoundis, PhD, formerly CEO of MaxiVAX, a private Swiss immuno-oncology company, joins Exacis as the Chief Business Officer.

Exacis was launched by Factor Bioscience with an exclusive license to its intellectual property for developing targeted, allogeneic cell therapies for cancer treatment. Factor CEO Matthew Angel, PhD,is the Chair of Exacis'Scientific Advisory Board and is joined on the SAB by Factor Co-Founder Christopher Rohde, PhD, Eric Westin, MD,and Gunnar Kaufmann, PhD. Exacis' Board of Directors is chaired by Mark Corrigan,MD, a highly successfuldrug developer,biotechnology CEO and Board Chairperson.

Commenting on the new endeavor, Dr. Fiore said, "This is a wonderful opportunity to create innovative, next-generation NK and T cell therapies to improve outcomes and experiences for patients with challenging liquid and solid tumors."

Exacis' Board Chairman Corrigan added, "The ground- breaking science Exacis has in-licensed, along with the team we are building, provide a strong foundation for developing successful targeted cell therapies for the treatment of cancer."

Exacis has secured initial seed funding and is seeking to raise Series A funding in early 2021. The company has initiated discussions with several potential development collaborators.

About Exacis Biotherapeutics

Exacis is a development stage biotechnology company focused on harnessing the human immune system to cure cancerby engineering off-the-shelf NK and T cell therapies aimed at liquid and solid tumors.Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use oftechnologies developed by Factor Biosciences.

About Factor Bioscience

Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. It actively licenses its technologies to entities wishing to conduct commercial research, sell tools, reagents and other products, perform commercial services for third parties, and develop human and veterinary therapeutics. Factor Bioscience is privately held and is headquartered in Cambridge, MA.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are ableto recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

SOURCE: Exacis Biotherapeutics

Read the rest here:
Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |...

Posted in Genetic Engineering | Comments Off on Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing For Targeted CAR-NK And CAR-T Cell Cancer Therapies | DNA RNA and Cells |…

Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 – GlobeNewswire

Posted: January 8, 2021 at 3:48 pm

OTTAWA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The global regenerative medicine market is representing impressive CAGR of 16.1% during the forecast period 2020 to 2027.

Regenerative medicine is the division of medicine that promotes methods to repair, regrow or replace injured or diseased tissues, organs or cells. Regenerative medicine comprises of the formation and use of remedial stem cells, manufacturing of artificial organs, and tissue engineering. The combinations of tissue engineering, cell and gene therapies can strengthen the natural healing procedure in the places it is desired most, or occupy the role of a permanently injured organ. Regenerative medicine is a rather new field that connects experts in chemistry, biology, engineering, computer science, robotics, medicine, genetics and other domains to find explanations to some of the most interesting medical problems confronted by humankind.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1176

Growth Factors:

Factors such as increasing prevalence of chronic disorders and genetic disorders, increasing popularity of stem cells, increasing number of trauma emergencies is driving the growth of regenerative medicine market. An illness or disorder that usually persists for 3 months or longer and might get worse over a period is termed as chronic disorder. Chronic diseases mostly occur in the elderly people and can typically be controlled but not repaired. The most prevalent types of chronic ailments are heart disease, arthritis, cancer, diabetes, and stroke. Cardiovascular disorders are the biggest cause of deaths worldwide. As per the WHO data, deaths due to cardiovascular disorders represent almost 31% of the deaths globally. Almost 85% of these demises are due to stroke and heart attack. Diabetes is another most prevalent chronic ailment that affects millions of people globally. According to International Diabetes Federation (IDF), around 463 million adults (age group: 20-79 years) are battling with diabetes and by the year 2045 the number will rise to a staggering 700 million. Furthermore, approximately 75% of all health care expenses are owed to chronic ailments. Four out of the five most costly health conditions are chronic disorders such as cancer, heart disease, pulmonary conditions, and mental disorders. Regenerative medicine approaches such as stem cell therapy can cure the chronic ailments such as diabetes and arthritis, which otherwise require lifetime of medications.

The role of regenerative medicine in post trauma recovery is constantly evolving as more and more research is showing positive results. The use of regenerative medicine can be a landmark moment in the history of healthcare that will transform the treatment of chronic ailments and trauma related conditions. Thus, the high incidence of chronic ailments is driving the growth of regenerative medicine market.

View Full Report with Complete ToC@ https://www.precedenceresearch.com/regenerative-medicine-market

Regional Analysis:

The report covers data for North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2019, North America dominated the global market with a market share of more than 45%. U.S. represented the highest share in the North American region primarily due to constant activity in the field of drug discovery and tissue engineering. Moreover, early adoption of latest healthcare technologies also contributed to the high market share of the United States.

Europe was the second important market chiefly due to favorable reimbursement scenario and presence of latest healthcare infrastructure. The presence of skilled researchers in the European region is also expected to boost the demand for regenerative medicine market in the near future. Asia Pacific is anticipated to grow at the maximum CAGR of around18% in the forecast period due to high incidence of trauma cases and chronic disorders. Latin America and the African and Middle Eastern region will display noticeable growth.

Report Highlights:

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1176

Key Market Players and Strategies:

The major companies operating in the worldwide regenerative medicine are Integra Life Sciences Corporation, Aspect Biosystems, Amgen, Inc., Medtronic plc, AstraZeneca, Novartis AG, Smith & Nephew plc, MiMedx Group, Shenzhen SibionoGeneTech Co., Ltd., and Baxteramong others.

High investment in the research and development along with acquisition, mergers, and collaborations are the key strategies undertaken by companies operating in the global regenerative medicine market. Recently Fuse Medical, Inc., an evolving manufacturer and supplier of innovative medical devices for the spine and orthopedic marketplace, declared the launch of FuseChoice Plus and FuseChoice Umbilical and Amniotic Membranes, and FuseChoice Plus Amniotic Joint Cushioning Fluid, the newest additions to a wide-ranging line of biologics product offerings.

Market Segmentation

By Product

By Application

By Geography

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1176

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

See the original post:
Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 - GlobeNewswire

Posted in Genetic Engineering | Comments Off on Regenerative Medicine Market to Reach Valuation US$ 23.7 Bn by 2027 – GlobeNewswire

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials – BioSpace

Posted: January 8, 2021 at 3:48 pm

CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells for treating cancers, launched today with over $50 million in financing to initiate multiple clinical trials in 2021. The Company combines advanced gene and cell engineering capabilities with substantial biologics knowledge to elucidate and redirect the power of myeloid cells to treat cancers, particularly solid tumors and those that are poorly served by existing therapies. Myeloid has advanced its lead development candidates through preclinical studies, implemented its manufacturing platform and plans to dose patients in the first half of this year.

The Company's scientific founders include Ronald Vale, Ph.D., a world-renowned biochemist and cell biologist, and executive director of the Howard Hughes Medical Institute (HHMI) Janelia Research campus; and hematologist, oncologist and Pulitzer-Prize winning author Siddhartha Mukherjee, M.D., D.Phil. Newpath Partners led the financing round with participation from 8VC, Hatteras Venture Partners and Alexandria Venture Investments.

With this funding, Myeloid will initiate clinical trials for the Company's programs, which target T cell lymphoma, glioblastoma and other solid tumors. The team will also continue to design and advance a broad pipeline of targeted myeloid cell therapies, including primed myeloid cells, myeloid multi-specific engagers and other development candidates created with Myeloid's novel mRNA delivery technologies. The Company expects to enter the clinic with its two lead programs in glioblastoma and T cell lymphoma in 2021.

"I believe Myeloid is best positioned to leverage the unique power of myeloid cells to help patients fighting cancers that until now, have been very difficult to treat," said Dr. Mukherjee. "Despite the promise of current cell therapies, many challenges remain when it comes to targeting specific types of cancers, including solid tumors, and in efficiently manufacturing treatments. I'm thrilled to help develop Myeloid's transformative treatment modality, which has the potential to overcome many of these challenges."

"Myeloid cells play a critical role in orchestrating the body's immune responses, including by directly killing cells, bacteria and viruses through a number of disease-fighting mechanisms," said Michael Dee Gunn, M.D., Professor of Medicine and Immunology at Duke University, and a pioneer in the research of molecular mechanisms of innate immunity and inflammation and a member of Myeloid's Scientific Advisory Board. "This novel class of cell therapies has strong potential to benefit patients with the highest unmet medical needs."

ATAKTM Cell Platform

The Company's ATAK platform was inspired by Drs. Vale and Mukherjee, who envisioned the disease-fighting power of myeloid cells versatile cells with effector functions capable of targeting and eliminating cancerous cells, along with other harmful cells in the body. Within the oncolytic setting, the ATAK platform is being applied to harness the innate abilities of myeloid cells, to specifically recognize and engulf cancer cells, to produce anti-tumor agents, promote anti-tumor adaptive immunity, alter the tumor microenvironment and ultimately to kill cancer. In addition to reprogramming monocytes to target difficult-to-treat cancers, the platform offers Myeloid and its partners many additional advantages, including novel mRNA-based protein and gene delivery, a library of intermixed cell receptors, and chimeric antigen receptors (CARs) that may be applied to enhance treatment effects or to engineer novel tri- and bi-specific cell engagers.

Myeloid is currently focused on advancing two categories of novel ATAK therapies: ATAK CAR monocytes and ATAK primed monocytes. ATAK CAR monocytes are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. ATAK primed monocytes function like cell vaccines, programmed to trigger T cells to kill cancer cells.

Manufacturing candidates from the ATAK platform benefit from speed and scalability in manufacturing process development. The Myeloid team can scale manufacturing rapidly, from product concept to clinical use. In addition, current products derived from the ATAK platform have a single-day cell manufacturing process. Given the observed strengths of the manufacturing process, Myeloid reasonably envisions same-day ATAK platform treatment, especially relevant upon clinical presentation of aggressive tumors. The Company is also in the process of developing "off the shelf" approaches in order to advance the full range of clinical delivery options.

Myeloid Leadership and Scientific Advisory Board

As co-founder and Chief Executive Officer of Myeloid, Daniel Getts, Ph.D., MBA, oversees the Company's portfolio and growth strategies. Dr. Getts is a repeat biotech entrepreneur, having led research at TCR2 through its IPO and the development of the first cell therapy to show clinical responses in ovarian cancer. Before that, he co-founded Cour Pharmaceuticals Development Company.

The Company's Scientific Advisory Board includes world-renowned scientists whose expertise span oncology, immunology, cell therapy, synthetic biology and genetic engineering:

"Our mission is to apply our energy and significant research capabilities to design and develop truly transformative treatments," said Dr. Getts. "We built Myeloid's ATAKTM platform to overcome many limitations of existing cell therapies, in part by embracing the natural tendencies of monocytes to penetrate solid tumors and catalyze immune reactions. By harnessing the power of monocytes, which are the cells that comprise the largest population of immune cells in the tumor microenvironment, we are working to bring new therapies to patients. We have also designed and successfully implemented an efficient, flexible manufacturing process that sets a new threshold for cell therapies. We are very pleased to have the support of this strong group of investors, who enable us to further develop the ATAK platform, to advance multiple solid tumor programs into the clinic, and to bring forward new transformative programs as we broaden Myeloid's pipeline."

"Myeloid cells are the body's front-line-disease-fighting tools, and they are critical in the orchestration of adaptive immune responses. These myeloid cells are overrepresented in solid cancers and I have been fascinated with their therapeutic potential since researching them during my medical training," said Thomas Cahill, M.D., Ph.D., Myeloid co-founder and Managing Partner of Newpath Partners. "Most other cell therapies focus on reprogramming the adaptive immune system and they have truly improved patient outcomes, especially with respect to liquid tumors. To expand on this promise, the next logical step was to empower the cells at the front lines of solid tumors. By engineering myeloid cells, the Company is developing an extremely versatile and potent class of new therapeutic agents. I look forward to continuing to support this team through their first wave of clinical trials and beyond."

About Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining biology insights with cutting-edge technologies to harness myeloid cells and eradicate cancer and other diseases. With broad clinical applications possible, the Company is presently advancing its cell therapy product candidates, derived from its ATAKTM platform technology, with initial applications in T cell lymphoma and a primed monocyte approach to treating glioblastoma. The ATAK platform is scalable to multiple treatment modalities and to other disease areas in collaboration. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. For more information, visit https://www.myeloidtx.com/.

Media Contact:Sarah SuttonGlover Park Groupssutton@gpg.com202-337-0808

View original content to download multimedia:http://www.prnewswire.com/news-releases/myeloid-therapeutics-launches-with-over-50-million-in-financing-and-two-clinical-trials-301201589.html

SOURCE Myeloid Therapeutics, Inc.

Excerpt from:
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials - BioSpace

Posted in Genetic Engineering | Comments Off on Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials – BioSpace

Illumination at the limits of knowledge – The Economist

Posted: January 8, 2021 at 3:48 pm

Jan 7th 2021

ALL THE technologies discussed in this report are moving forward apace. The companies which provide machinery to solar-cell manufacturers are ceaselessly trying to make more efficient use of silicon and less costly modules. In universities and elsewhere researchers are looking at ways to add a second layer to such cells so as to capture energy at wavelengths silicon ignoresthough their best attempts so far do not last very long outdoors.

Advances in manufacturing and design are making LEDs ever better sources of illumination. In more and more screens they backlight the liquid-crystal shutters which brighten pixels by detenebration. Some screens already do without shuttering, using liquid-crystal-free arrays of micro-LEDs to produce images that offer better contrast and use less energy. In information technology the division of labour that sees data processing done by electrons and data transmission by photons is under attack; switches that could be programmed to do some information processing while keeping that information in the form of photons would allow data to flow around data centres more quickly and efficiently. Laser beams of slightly different wavelengths are being packed ever more densely into optical fibres, with more bits encoded into every symbol stamped on to their light. The current record for data transfer down a single fibre, held by researchers at UCL, a British university, is 178 terabits a second.

But if you want to see lasers which push the boundaries of the possible in the most dramatic of ways, you have to turn to those made, not for practical applications, but to further science. Wherever researchers require ludicrous amounts of power or precision, theres every chance that they are using a laser, some sort of digital photon detector, or both. To see the cutting edge of what light can do, head for a lab.

The National Ignition Facility (NIF) at Lawrence Livermore National Laboratory in California is a case in point: walking its halls evokes a sense of the technological sublime which is all but visceral. The 192 laser beams from the 100-metre-long, xenon-pumped beamlines that fill its two warehouse-sized clean rooms converge on a peculiarly perforated spherical chamber. When NIF is operational a tiny bubble at the centre of that chamber is illuminated with 500 terawatts, which is to say 500,000GW.

Given that the worlds total electricity generating capacity is less than 5TW, how is a 500TW system possible? The answer is brevity. Because power is energy divided by time, a relatively small amount of energy can provide a huge amount of power if it is delivered quickly enough. The NIF fires for only a few tens of nanoseconds (billionths of a second) at a time. Each blink-and-you-miss-it 500TW blast thus delivers only a kilowatt-hour or so of energy.

Using such a gargantuan device to provide such a modest amount of energy seems bizarre. But NIFs job requires the energy to be delivered with great spatial precision and almost instantaneously. Only then can it heat the lasers tiny targets to temperatures and pressures otherwise reached only in the centres of stars and the blasts of nuclear weaponsconditions which can fuse atomic nuclei. Congress paid billions for the NIF on the basis that it might open the way to making nuclear fusion of this sort a practical energy source. It has not delivered on those dreams. But it has provided new insights into astrophysics as well as experimental data relevant to the design and maintenance of hydrogen bombs, which is Lawrence Livermores main concern.

Physicists are not the only scientists entranced by lasers. One of the workhorses of genetic engineering is green fluorescent protein (GFP). The instructions for making GFP are easily added to genes for other proteins. When poked with finely focused lasers these modified proteins fluoresce, thus revealing their whereaboutsa handy way of learning which proteins cells put where.

A remarkable refinement of this technique, first demonstrated in 2011, is to turn the cell itself into a laser. Engineer a cell to produce GFP, put it between two mirrors and pump energy in and the proteins light will be amplified in just the same way as it would in a piece of ruby or neodymium-doped glass. Light-emission microscopy based on this possibility amplifies the light given off by fluorescent proteins and other light-emitting markers.

Photons can also be used to change how cells behave. By engineering proteins to be sensitive to light and then turning that light on and off, researchers can change what cells doincluding the ways they do, or dont, transmit nerve impulses. Laser light flashed on to the nerves of a suitably engineered flatworm, or shone down optical fibres into the brain of a mouse, allows researchers to turn different parts of the nervous system on and off and observe the changes in behaviour that follow. This optogenetic puppeteering provides all sorts of new insights into the machinery of the brain. With all due respect to those using photons to explore the strange interconnectedness of things in quantum mechanicswhich Einstein famously described as spookyphotons that can literally change a mind in mid-thought may be the spookiest of all.

The degree to which light-based techniques are changing sciences across the board can be seen in the past decades decisions by the Nobel Physics Committee. In 2014 the committee recognised a physical breakthrough in the production of lightthe development of blue LEDs, a technical tour de force which made the production of white light cheaper and easier than ever before. Since then the physics prize has been awarded to three different ways of using lasers either for experiments in the lab or observations of the world. A tour of these prize-winning accomplishments allows a last celebration of this golden age of light.

Start with pure power. A technique called chirped-pulse amplification, developed by Donna Strickland and Grard Mourou when they were both at the University of Rochester, allows lasers far more powerful than the NIFlasers which work in the petawatt range. It provides a way around the unfortunate fact that, above a certain power level, even a very short pulse will melt any laser trying to amplify it further. Chirp amplification solves the problem by stretching pulses out in both space and time. An intense packet of photons that is, say, a millimetre long, and thus passes through any machine in just three trillionths of a second, can be chirped into one that is a metre long and lasts a full three billionths of a second. This stretched pulse is low-power enough to be amplified, after which it can be compressed back into its original form as a burst just as short as ever but now containing many more photons.

Labs around the world now use this technique to produce bursts of light both far shorter and far more powerful than those at NIF using much cheaper equipment. This allows them to study nuclear processes that are even more extreme than fusion. If the pulses can be made 1,000 times shorter stillwhich Dr Mourou, at least, thinks is possible, given a decade or sothey could achieve something no other technology has yet managed: the creation of matter (and antimatter) from scratch.

Einsteins work dispensed with the need for an all-pervading luminiferous aether. But the fields evoked by quantum electrodynamics (QED), the mid-20th-century culmination of work on electromagnetism, quantum theory and relativity, populate empty space with something else instead: very faint possibilities. And QED says that, if light gets sufficiently intense, its photons will interact with these possibilities to bring forth brand new electrons from empty space. Einsteins insight that mass can be converted into energy has been proven many times, most terribly in nuclear weapons. Creating material particles from massless light alone would be a remarkable turning of the tables, and one that ought to provide new insight into the quantum fields involved.

After power, pressure. The momentum of photons is tiny; but when applied to tiny things it can do useful work. In the 1960s Arthur Ashkin of Bell Labs realised that, if a small transparent object is placed on the edge of a laser beam it will move to the beams centre (provided that the beam is brighter at the centre than the edge). This is because the photons that pass through the object have their path bent outward, away from the beam: conservation of momentum requires the object thus diverting them to move in the opposite direction. If, once caught up in the beam, the object strays from its bright centre, the light pressure will bring it back.

In the 1970s Dr Ashkin put this idea into practice, using laser beams as optical tweezers with which to manipulate microscopic beads. In the 1980s he got the technique to work on individual bacteria and virus particles, while his student Steven Chu used a variant to trap individual atomswork that won Dr Chu and colleagues a Nobel prize in 1997. The increasing use made of his tweezers in biology saw Dr Ashkin follow in his students footsteps in 2018, sharing the prize with Dr Strickland and Dr Mourou.

And then there is precision. Einsteins general theory of relativity, promulgated in 1915, explains gravity in terms of the distortions masses impose on spacetimespacetime being, to Einstein, simply the thing that clocks and rulers measure. His special theory of relativity had laid out the case for light being the ultimate ruler, a view that measurement professionals now share; the General Conference on Weights and Measures defines the metre not as the length of a specific rod in a vault in Paris, as it once did, but as the distance a photon in a vacuum travels in 1/299,792,458 of a second. Thus if you want to see ripples in spacetimesuch as those which relativity says must be produced when two very large masses pirouette around each otherlight is the best sort of ruler to use.

The Laser Interferometer Gravitational-wave Observatory (LIGO) consists of two such rulers. Its twin detectors, one in Louisiana and one in Washington state, both feature 4km-long perpendicular arms along which laser beams of truly phenomenal stability bounce back and forth (see chart). Instruments mounted at the point where the beams cross compare their phases in order to detect transitory differences in the arms lengths. Their precision is equivalent to that which would be needed to detect a hairs-breadth change in the distance to a nearby star.

On September 14th 2015 LIGO picked up the shiver in spacetime produced by the merger of two black holes 1.3bn light-years away. In 2017 the Nobel Physics Committee, free of naysaying ophthalmologists, awarded the prize to Rainer Weiss, Kip Thorne and Barry C. Barish, the three scientists who had done most to make that observation happen.

Their extraordinary measurement was treated, quite rightly, as a slightly late 100th-birthday present for Einsteins truly remarkable intellectual achievement. It was also an extraordinary demonstration of what can be done with photons. A century of work by scientists and engineers has taken the energy packets that Einstein first imagined in 1905 and produced a range of technologies with capabilities little short of the miraculousa collective achievement far greater than any single act of genius. Relativity is remarkable. Putting photons to use has been revolutionary.

This article appeared in the Technology Quarterly section of the print edition under the headline "New enlightenments"

See the article here:
Illumination at the limits of knowledge - The Economist

Posted in Genetic Engineering | Comments Off on Illumination at the limits of knowledge – The Economist

Juggernaut Is Forming His Own Team of Reformed Supervillain – Screen Rant

Posted: January 8, 2021 at 3:48 pm

Juggernaut has put together a group of reformed villains that are way down on the C-list but they could end up being a strong team

Juggernaut is rarely a team player, but the copper-colored killing machine is trying to rebuild his image, and do some good in the process, by building a new super team. Sure its made of former villains (and potentially one Nazi) but friends are hard to come by for Cain Marko.

Fabian Nicieza and Ron Garney set the stage at the end of Juggernaut #5 for Cain Marko to build a new life. This whole run of comics has been about shedding Cains former flaws and helping out the little guys. Marko is usually cast as the villain (to his benefit in many cases) but this story is about redemption and Marko recognizes he will fail if he sets out on his own.

Related: Juggernaut is Officially A Hero, But He's Still Just As Deadly

A lot of super teams end up at each others throats before long, but the group of reformed villains Juggernaut put together is small enough to stay tight-knit. Its composed of Primus, an android made by Captain America villain Arnim Zola (more on him later), and Quicksand. The teaser sting at the end of the comic claims Zola is not affiliated with this new supergroup. But seeing how he made the Primus, who is a prime example of the Nazi geneticist's prowess, its likely Zola will be roped in.

Primus is a shapeshifting android created to ally the Nazis but revolted against his creator (why dont mad scientists ever read Frankenstein) only to make amends and start working for him again decades later. The two, the self-deprecating Primus and self-aggrandizing Zola, set up shop in North Dakota which is where Juggernaut meets up with them to reformulate Quicksand. Quicksand (a shapeshifting sand lady) is a forgettable Thor villain but has cropped up here and there over the decades, usually as a part of villainous teams - when she wasnt imprisoned on the Raft, Marvels supermax prison for super baddies.

Juggernautspent the bulk of the comic tutoring a young mutant and eventually convincing her to ship off to Krakoa the mutant homeworld and safe haven created to protect mutantkind. This streak of do-goodery convinced Juggernaut he needs to care for other superheroes and supervillains that arent of the mutant variety. Juggernaut is often seen alongside mutants and is the step-brother to Charles Xavier, but Cain Marko gets his powers from a gem called Cyttorak, not mutant powers. Juggernaut saved the young mutant D-Cel from being experimented on, compelling her to ask for asylum on Krakoa.Juggernaut'smotivations have usually been greed or gore so this is a nice change of pace for the character.

This supergroup, however, is a bit of a gang of C-listers. And its going to be a real hard sell that they are a group of reformed altruists with a former Nazi sympathizer like Arnim Zola. After all, he transferred his consciousness into a robot and is reborn in the modern age with some old-fashioned ideas, like fascism and genetic engineering. And unlike Marko who genuinely seems like he wants to turn over a new leaf, Zola has no such fantasies. Once a Nazi always a Nazi. He condemns this supergroup and if the tease at the end of the comic is to be believed, then he wont be a part of it. But hes still tied to his creation (Primus) and could be the future demise of this group.FutureJuggernautstories are going to be fascinating to see what comes next for him, the supergroup, and Zola.

Next: Marvel Reveals Juggernaut's Weirdest Weakness

Why Marvel's Phoenix Force Hates Mutants (But Loves Redheads)

Full-time janitor, part-time writer and reading comics in any spare time.

See the rest here:
Juggernaut Is Forming His Own Team of Reformed Supervillain - Screen Rant

Posted in Genetic Engineering | Comments Off on Juggernaut Is Forming His Own Team of Reformed Supervillain – Screen Rant

5 trends fueling food and beverage innovation in 2021 – Food Dive

Posted: January 8, 2021 at 3:48 pm

After an unpredictable and turbulent 2020, many are hoping 2021 will bring more stability. But the pandemic is expected to still hold sway and influence some of the biggest food and beverage trends in the coming months.

One major theme that will continue in the new year reflects what many wish 2020 had more of: health. Companies will be looking to launch foods and beverages with immunity-boosting ingredients. The plant-based and alternative space will also see continued growth, but take different shapes with new ingredients, from algae to mushrooms.

Technology will also arise as a major trend as the calendar turns over. Since food and worker safety was in the spotlight this past year, new developments will promise to give consumers confidence in their food. Tech, like CRISPR, will also help create innovations in food that meet the growing demands of consumers as hot trends, like global flavors, dominate the space.

After conversations with industry experts and analysts, here is a breakdown of the five biggest trends that Food Dive predicts will impact the food and beverage industry in 2021.

Courtesy of Chobani

Consumers spent most of last year focused on trying to stay healthy and that desire seeped into their food choices. According to research from ADM, the pandemic made more people interested in foods that benefit their immunity, and experts are predicting that will continue in 2021.

A lot of companies will be jumping on this immunity bandwagon, said Kara Nielsen, director of Food & Drink at WGSN, a trend forecasting company under Ascential.

In a report, WGSN identified immunity-supporting ingredients as a key theme for 2021. Product developers are learning from consumer demand in the past year. From elderberries and probiotics to turmeric and moringa, WGSN said the ingredients with immunity claims are among those poised for further growth.

Nielsen said that companies are also looking to add benefits and claims to their products that prioritize health, like yogurt companies launching into probiotics, and highlighting other qualities such as sugar reduction.

Immunity-boosting ingredients have seen a sales bump already, and more companies are expanding their portfolios with those features. Chobani recently announced a line of yogurt that spotlights probiotics, and Uncle Matts launched an Ultimate Immune Orange Juice Beverage.

Now once everyone has the vaccine, will people pull back from some of this? I think that remains to be seen, but I think people will stay concerned throughout next year, Nielsen said.

According to the Innova Consumer Survey 2020, six out of 10 global consumers are increasingly looking for products that support their immune health, with one in three saying that their concerns increased in 2020. Innova identified immunity as a top trend for the next year.

Lu Ann Williams, director of insights and innovation at Innova Market Insights, said immunity is an opportunity that can be broader than just taking Vitamin C or zinc. Williams pointed to botanicals as an example of an ingredient that brings an active health benefit, as well as color and flavor that tick the natural box.

"Consumers are interested in foods that are naturally high in nutrients to promote their immunity, Williams said. I think there is a big opportunity to combine hero ingredients that bring nutritional benefits whose benefits are easy to communicate."

Early in the pandemic, headlines across the country focused on outbreaks at food and meat manufacturing plants. As a result, more consumers have looked critically at where their food comes from and who makes it. Experts say that theme will continue in the next year, with technology working to make food and workers more safe.

Innova Market Insights said that transparency throughout the supply chain will dominate as the top trend of the year, with six in 10 consumers interested in knowing more about their foods origin. The firm said that can be achieved with new packaging technologies such as invisible barcodes.

Williams said trends develop over years, and since Innovas top trend last year was storytelling, the extra layer this year is transparency.

Transparency will be crucial in helping consumers understand and accept the products, she said.

Innovations are already debuting to spotlight this trend, like digital expiration date labels that offer real-time monitoring of food quality.

In addition to smart packaging, food producers are also increasingly using blockchain to track products from farm to table, including coffee and turkeys. Blockchain can help if there is a recall and can provide better traceability.

Nielsen at WGSN said consumers are looking for more promises of safety, and food suppliers need to communicate more about their efforts. But there is movement in the space with big companies like Nestl starting to adopt more blockchain.

It's still kind of high level I don't think so much down on a consumer level but I think it will get down there over the course of the year so that people understand a little bit better, Nielsen said.

Meat processors have also already started to expedite their plans to incorporate more automation and robotics to elevate food safety as the pandemic ravages their workforce. For example, inside the Tyson Manufacturing Automation Center, engineers are working to develop innovative technology like a robotic camera that could detect defects on products.

Keith Belk, head of Colorado State Universitys animal sciences department, said theres been a huge increase in the rate of development of those technologies, both in the U.S. and abroad.

Other technological innovations for food safety have arisen during the pandemic. For example, companies started to look at wastewater to catch coronavirus spikes. Belk said they learned they could use that same technology to look at foodborne pathogens such as salmonella or E. coli.

"If you're looking for something good out of the pandemic, which there's not very much, that's a good thing that came out of it,"Belk said.

Plant-based food has been a major trend in the last several years. And while sales numbers for 2020 have not yet been crunched, they are sure to be record-setting. In a study last month, Packaged Facts estimated plant-based dairy and egg sales would register at about $4.3 billion, and would continue to grow at an annual rate of 6%. And through Oct. 3, according to Nielsen, meat alternative sales were up 129% compared to the first nine months of 2019.

As the segment continues to hit its stride, both new and old players are bound to launch products and find success in 2021. But experts say they likely won't reuse the same old ingredients in different ways. Where the plant-based space is currently dominated by pea, soy and wheat protein, expect to see more products featuring ingredients made from different plants in 2021.

Phil Kafarakis, president emeritus of the Specialty Food Association and international food industry advisor, said this movement started in plant-based dairy. The soy milks and almond milks that dominated the plant-based dairy case in years past are now joined by dairy products sourced from a host of other plants, including oat, quinoa, hemp and macadamia nut. In other sections of the store, cauliflower has become a common substitute for many grains, including wheat and rice. And pulses ranging from chickpeas to fava beans are starting to appear as snacks and components of plant-based butters and creamers.

It's been accelerating, Kafarakis said. ...During this period of COVID, once they got past all the hoarding, people were into understanding that they can experiment with brands that traditionally they might not have tried before. So some of these products are out there and they're creating a lot of excitement, so I think you're gonna see that become more mainstream.

Sabina Vyas, senior director of strategic initiatives and communications at the Plant Based Foods Association, sees three main categories of new plant-based and alternative ingredients coming into the fore in 2021: algae, fungi and mushrooms, and legumes and pulses. These ingredients have several advantages: They are sustainable, have vital nutrients, and have good taste and textures. They also are relatively inexpensive and easy to source.

Consumers "want these foods to taste good," Vyas said. "They want to see that these foods are also sustainable and better for them. ... So manufacturers are ... working accordingly. I think they're unleashing the possibilities of what's available in plants and the fungi kingdom.

Michael Robbins, a spokesperson for the Plant Based Foods Association, added that alternative plant-based ingredients are getting to be more popular because stores have limited amounts of shelf space. New products need to offer something unique to get on the shelf, and new base ingredients can help differentiate products.

While demand for global flavors has been on the upswing in recent years, the pace is expected to intensify in 2021 as the effects of the pandemic linger and consumer interest in new and novel tastes continues to grow.

Going into 2021, there seems to be heightened interest compared to the start of 2020 as consumers havent traveled as much as normal or dined out as much as normal so they are looking for food at home to generate some of the novelty and interest theyd usually get from other sources, said Neil Saunders, managing director of GlobalData's retail division.

Analysts who follow the food space said a growing interest in wellness fueled by the pandemic has elevated flavors that consumers view as healthy. This could bode well for ingredients such as traditional berries and fruits, butterfly-pea flower and moringa, Saunders said.

At the same time, civil unrest across the country has focused attention on cultures and ethnic groups whose offerings may not have been as explored before. Consumers not only want to try something new but also support products that are authentic and come with a story.

Global flavors most likely to attract added consumer attention in 2021 include matcha and moringa in Asia and earthy offerings like elderberry, cinnamon and rhubarb. Those ingredients could eventually become more prominent in U.S. foods. In America, spicy offerings like hot sauces and peppers, as well as African fare, are expected to be more prominent.

Companies that offer ready-to-eat meals, sauces, soups and meal kits with these flavors are poised to succeed, said Elly Truesdell, a partner at Almanac Insights who formerly oversaw local brands and product innovations for Whole Foods Market.

As insatiable as Americans are for global flavors, there is also still a real insecurity around getting it right and cooking for ourselves, she said.

Few technologies have transformed development of food production during the last few decades as much as genetic modification. Now, efforts to improve the taste, texture and production of fruits and vegetables are being spurred on by CRISPR and other gene-editing techniques that promise to do all these things faster and for a fraction of the cost.

Consumers will see food with a lot of different traits, such as fresher and tastier, "although they will not necessarily know they are gene edited, said Jennifer Kuzma, a professor at North Carolina State University and co-director of its Genetic Engineering and Society Center. I do think now were going to see gene editing and CRISPR-based crops enter the market in 2021.

Early genetic engineering focused predominantly on crops such as soybeans and corn grown by farmers to boost yields and make them resistant to pests or able to withstand chemical treatments. But more work today is being done on consumer-centric foods like mushrooms, apples, potatoes and lettuce that can be tweaked to include attributes important to consumers.

Pairwise, for example, is tapping into CRISPR gene-editing technology to remove the bitterness from a nutrient-dense green, the seeds from the outside of a blackberry and the pit in a cherry.

Sure there is risk there, but what were saying is that we believe the technology is good enough and it can deliver things that are good enough for people, said Ryan Rapp, who focuses on fruit as the head of product discovery at Pairwise. As long as we stick to our values and transparency and being open with them, I think consumers are going to love this.

Still, some people are concerned that companies using CRISPR and other technologies arent being transparent enough, and repeating the same mistakes as early pioneers of genetic engineered crops. They also worry USDAs regulatory process isnt robust enough.

Gregory Jaffe, director of the biotechnology project at the Center for Science in the Public Interest, said people want to know first if the technology used in their food is safe and then how it benefits them. Transparency is going to be important, he said. Consumers want to know more and more about the food and where their food comes from, and so it will be critical to acceptance.

Original post:
5 trends fueling food and beverage innovation in 2021 - Food Dive

Posted in Genetic Engineering | Comments Off on 5 trends fueling food and beverage innovation in 2021 – Food Dive

Biotech Cotton Key to Eliminating Devastating Pest from US and Mexico – Seed World

Posted: January 8, 2021 at 3:48 pm

For much of the past century, the invasive pink bollworm wreaked havoc in the southwestern United States and northern Mexico inflicting tens of millions of dollars in damage annually to cotton on both sides of the border.

A multifaceted strategy combining genetically engineered cotton with classical pest control tactics eradicated the pink bollworm from cotton-producing areas of the continental U.S. and Mexico, according to a new study published inProceedings of the National Academy of Sciences.

Although pink bollworm remains a daunting pest in over 100 countries, our strategic coalition rid the U.S. and Mexico of this invasive insect, said lead study authorBruce Tabashnik, a Regents Professor in the University of ArizonaDepartment of Entomology.

By analyzing computer simulations and 21 years of field data from Arizona, we discovered that genetically engineered cotton and the release of billions of sterile pink bollworm moths acted synergistically to suppress this pest, said Jeffrey Fabrick, a co-author of the study and a research entomologist with the U.S. Department of Agricultures Agricultural Research Service.

According to the study, the eradication program saved U.S. cotton growers $192 million from 2014 to 2019. Through environmentally friendly approaches, it also helped to reduce insecticides sprayed against all cotton pests by 82% and prevented the application of over a million pounds of insecticides per year in Arizona.

A Long Road to Suppression

Native to Australasia a region that comprises Australia, New Zealand and some neighboring islands the pink bollworm is one of the worlds most invasive insects. After female moths lay their eggs on cotton plants, the caterpillars hatch, bore into cotton bolls and devour the seeds within. Their feasting disrupts production of cotton lint.

This voracious pest was first detected in the U.S. in 1917. Using field data from 1969, the new study estimates that over 200 billion pink bollworm caterpillars infested cotton fields in Arizona that year. In 1990, the pest cost Arizona cotton growers $32 million in damages, despite $16 million invested in insecticides to control it.

The tide began to turn in 1996, with the introduction of cotton genetically engineered to produce proteins from the bacteriumBacillus thuringiensis. The proteins in Bt cotton kill pink bollworm and other caterpillar pests but are harmless to people and most beneficial insects.

Although Bt cotton kills essentially 100% of susceptible pink bollworm caterpillars, the pest rapidly evolved resistance to Bt proteins in laboratory experiments at the University of Arizona and in Bt cotton fields in India.

To delay pest resistance, UArizona scientists worked with farmers to develop and implement a strategy of planting non-Bt cotton refuges to allow survival of susceptible insects. Tabashniks team also determined the mutations that cause resistance in the lab and used DNA screening to monitor for those adaptations in the field.

Within 10 years, the use of Bt cotton reduced pink bollworm populations by 90%. For the first time since the pests arrival, eradication seemed within grasp.

Everything but the Kitchen Sink

In contrast with the rapid evolution of pest resistance to genetically engineered crops elsewhere, Bt cotton was suppressing this pest in Arizona for a decade, Tabashnik explained. We said, Lets take this a step further. Lets throw everything but the kitchen sink at it and get rid of it. If not forever, for as long as we can sustain it.'

In a concerted, binational effort, University of ArizonaCooperative Extensionand research scientists joined forces with cotton growers, the biotech industry and government partners to devise the first program of its kind to eradicate the invasive pest.

In addition to traditional pest control tactics, such as plowing cotton fields after harvest to reduce the pests overwintering survival, a novel strategy largely replacing refuges of non-Bt cotton with mass releases of sterile pink bollworm moths was initiated in Arizona in 2006.

The sterile moths were released from airplanes by the billions to overwhelm field populations of the pest. In concert, the U.S. Environmental Protection Agency waived the requirement for planting refuges, allowing farmers in Arizona to plant up to 100% Bt cotton.

To test the success of this multipronged attack, scientists with the University of ArizonaCollege of Agriculture and Life Sciences conducted computer simulations and analyzed field data collected in Arizona from 1998 to 2018. Their results show neither of the two tactics would have worked alone.

In this era plagued by invasive organisms, as well as doubts about the power of science and controversy about genetic engineering, the study exemplifies the tremendous benefits of collaboration and synergy between biotechnology and classical tactics, Tabashnik said. We hope the concepts illustrated here will inspire integrated approaches to combat other invasive life forms.

Source: University of Arizona

View post:
Biotech Cotton Key to Eliminating Devastating Pest from US and Mexico - Seed World

Posted in Genetic Engineering | Comments Off on Biotech Cotton Key to Eliminating Devastating Pest from US and Mexico – Seed World

Page 785«..1020..784785786787..790800..»